Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Prospective Trial of Dabrafenib and Trametinib With Stereotactic Radiosurgery in BRAF Mutant Melanoma Brain Metastases

NCT01721603 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01721603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01721603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Prospective Trial of Dabrafenib and Trametinib With Stereotactic Radiosurgery in BRAF Mutant Melanoma Brain Metastases
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2013
Completion date
January 31, 2016
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brafv600e melanoma patients